Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEco Animal Regulatory News (EAH)

Share Price Information for Eco Animal (EAH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 112.50
Bid: 110.00
Ask: 115.00
Change: 0.00 (0.00%)
Spread: 5.00 (4.545%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 112.50
EAH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Statement re ECO Animal Health and The Pirbright Institute sign second poultry vaccine development licencing deal.

11 Sep 2019 07:00

 

11 September 2019

ECO Animal Health Group plc

(AIM: EAH)

ECO Animal Health and The Pirbright Institute sign second poultry vaccine development licencing deal

ECO Animal Health Ltd (ECO), a wholly owned subsidiary of ECO Animal Health Group plc, is pleased to announce that it has entered into a second worldwide exclusive research partnership with The Pirbright Institute, United Kingdom, to develop another novel vaccine for use in chickens.

Innovative technologies developed at Pirbright will use a Marek’s disease virus vector to express multiple protective components against the economically important poultry viral diseases of infectious bursal disease virus (IBDV), Newcastle disease virus (NDV) and infectious laryngotracheitis virus (ILTV) which cause significant systemic and respiratory damage.

The global poultry biologicals market is worth c. $2.3 billion and forecast to grow with a CAGR of 5-6%. The Marek’s disease, IBDV, NDV and ILTV segments are collectively worth c. $470 million.

Professor Venugopal Nair, Head of Avian Viral Diseases at the Pirbright Institute, states: “The novel vaccine will have the potential to induce simultaneous protection against Marek’s disease as well as the other major diseases caused by IBDV, NDV and ILTV that threaten poultry health and production worldwide.”

Commenting Marc Loomes, CEO of ECO Animal Health Group plc, said: “We are delighted to have partnered with the Pirbright Institute again to develop another novel vaccine for use in chickens. The use of the Marek’s disease vector in this technology is a significant advancement over other recombinant vaccines and will help widen the potential use of this vaccine in broilers and in breeding stock.”

Enquiries:

 

 

 

ECO Animal Health Group plc

 

Marc Loomes, CEO

020 8447 8899

 

 

N+1 Singer (Nominated Advisor and Joint Broker)

020 7496 3000

Mark Taylor

 

Alex Bond

 

 

 

Peel Hunt (Joint Broker)

020 7418 8900

James Steel

 

Dr Christopher Golden

 

 

 

IFC Advisory

020 3934 6637

Graham Herring

 

Miles Nolan

 

Zach Cohen

 

 

 

The Pirbright Institute

0148323 2441

About ECO Animal Health Ltd

ECO Animal Health based in London U.K. is a leader in the development, registration and marketing of pharmaceutical products for global animal health markets. Its products for these growth markets promote well-being in animals and include the novel antimicrobial, Aivlosin®, as well as a range of generic therapeutic products.

About The Pirbright Institute

The Pirbright Institute is a world leading centre of excellence in research and surveillance of virus diseases of farm animals and viruses that spread from animals to humans. It receives strategic funding from the Biotechnology and Biological Sciences Research Council (BBSRC), and works to enhance capability to contain, control and eliminate these economically and medically important diseases through highly innovative fundamental and applied bioscience.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190910005895/en/

Copyright Business Wire 2019

Date   Source Headline
25th Apr 20247:00 amRNSTrading Update on year ended 31 March 2024
8th Apr 20247:00 amRNSHolding(s) in Company
4th Apr 20247:00 amRNSDisposal of non-core product line
22nd Mar 20247:00 amRNSShare Awards to Executive Directors
21st Mar 20249:13 amRNSReplacement: Trading Update
21st Mar 20247:00 amRNSTrading Update
19th Mar 20249:40 amRNSGeneral Meeting Result
27th Feb 20247:00 amRNSPublication of Notice of General Meeting
6th Feb 20247:00 amRNSTrademark Approval for ECOVAXXIN® family in the EU
8th Jan 20247:00 amRNSDisposal of Freehold Properties
5th Jan 20245:05 pmRNSHolding(s) in Company
5th Jan 20245:00 pmRNSHolding(s) in Company
22nd Dec 20237:00 amRNSDeferred Option Awards to Executive Directors
1st Dec 20237:00 amRNSDirector/PDMR Shareholding
27th Nov 202310:00 amRNSInvestor Presentation
27th Nov 20237:00 amRNSResults for the six months ended 30 September 2023
14th Nov 20233:00 pmRNSHolding(s) in Company
9th Nov 20237:00 amRNSCapital Markets Day Events
24th Oct 20237:00 amRNSNew USA and Canada label claim for Aivlosin®
28th Sep 20237:00 amRNSESG Rating
7th Sep 20232:57 pmRNSResult of AGM
10th Aug 20237:00 amRNSNotice of AGM
21st Jul 20234:25 pmRNSPosting of the Annual Report and Accounts
10th Jul 20237:00 amRNSFinal Results for the Year Ended 31 March 2023
5th Jul 20237:00 amRNSNotice of Results & Investor Presentation
6th Jun 20237:00 amRNSIssue of Equity and Total Voting Rights
18th May 20237:00 amRNSHolding(s) in Company
23rd Mar 20237:00 amRNSTrading Update
8th Mar 20237:00 amRNSAnimal Health Innovation Summit
27th Feb 202310:37 amRNSDirector/PDMR Shareholding
24th Feb 20233:19 pmRNSChange of Registered Address
17th Feb 20231:41 pmRNSHolding(s) in Company
13th Feb 20231:55 pmRNSHolding(s) in Company
9th Feb 20237:00 amRNSHolding(s) in Company
9th Feb 20237:00 amRNSHolding(s) in Company
8th Feb 20237:00 amRNSDirector/PDMR Shareholding
20th Jan 202312:14 pmRNSHolding(s) in Company
13th Dec 20223:50 pmRNSDeferred Share Option Awards
30th Nov 20223:01 pmRNSDirector/PDMR Shareholding
25th Nov 20221:37 pmRNSDirector/PDMR Shareholding
23rd Nov 20227:00 amRNSResults for the six months ended 30 September 2022
22nd Nov 20227:00 amRNSInvestor Presentation covering Interim Results
14th Nov 20227:00 amRNSChange of Auditor
31st Oct 20227:00 amRNSBlock listing Interim Review
24th Oct 20221:30 pmRNSHolding(s) in Company
24th Oct 20221:28 pmRNSHolding(s) in Company
26th Sep 20224:01 pmRNSResult of AGM
5th Sep 20221:00 pmRNSInvestor Presentation covering Full Year Results
2nd Sep 20227:00 amRNSPublication of Annual Report and Notice of AGM
31st Aug 20227:00 amRNSFinal Results for the Year Ended 31 March 2022

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.